Headache induced by serotonergic agonists - A key to the interpretation of migraine pathogenesis?

Cephalalgia

Volumn 17, Issue 1, 1997, Pages 3-14

  Panconesi, A ^a   Sicuteri, R ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5 hydroxytryptamine; fenfluramine; m chlorophenylpiperazine; migraine; sel ective 5HT reuptake inhibitors

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; BUSPIRONE; ERGOT ALKALOID; FENFLURAMINE; FLUOXETINE; NITRIC OXIDE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN;

ELECTROPHYSIOLOGY; HEADACHE; HUMAN; HYPERSENSITIVITY; MIGRAINE; RECEPTOR BINDING; REVIEW; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; YAWNING;

ANIMALS; FENFLURAMINE; HEADACHE; HUMANS; HYPERSENSITIVITY; PIPERAZINES; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0031047754     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1701003.x     Document Type: Review

References (147)

1. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-65
2. Silberstein SD. Serotonin (5HT) and migraine. Headache 1994;34:408-17
3. Panconesi A. 5-Hydroxytryptamine parameters in the periphery: how useful are they in the study of headaches? J Serotonin Res 1995;2:117-37
4. 1C receptor activation: a key step in the initiation of migraine? Trends Pharmacol Sci 1989;10:307-9
5. 1C receptor agonism as an initiating event in migraine. In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992:200-12
6. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
7. Fozard JR. The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? Arch Int Pharmacodyn 1995;329:111-9
8. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5HT) and the initiation of migraine: new perspectives. Naunyn-Schmiedebergs Arch Pharmacol 1994;350:225-9
9. 2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995; 16:105-10
10. 2C receptor blockade? Life Sci 1994;54:641-4
11. Sicuteri F, Poggioni M, Panconesi A. Upregulation of pain transmission from deficient serotonergic analgesia in migraine. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM, editors. Serotonin: from cell biology to pharmacology and therapeutics. Dordrecht: Kluwer Academic 1990:391-404
12. Sicuteri F. Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity). Headache 1972;12:69-72
13. Sicuteri F. Pain syndrome in man following treatment with p-chlorophenylalanine. Pharmacol Res Commun 1971;3:401-7
14. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988;4 3:605-9
15. Gordon ML, Lipton RB, Brown S-L, Nakraseive C, Russell M, Pollack SZ, et al. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated. Cephalalgia 1993;13:400-5
16. Brewerton TD, Murphy DL, Lesem MD, Brandt HA, Jimerson DC. Headache responses following m-chlorophenylpiperazine in bulimics and controls. Headache 1992;32:217-22
17. Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Quearry B, George DT, et al. Neuroendocrine responses to m-chlorophenylpiperazine and 1-tryptophan in bulimia. Arch Gen Psychiatry 1992;49:852-61
18. Spierings ELH. Hypothesis: serotonin-1C receptor activation in migraine: an alternative point of view with therapeutic implication. Headache 1991;31:546-9
19. Silberstein SD, Fozard JR, Murphy DL. More on mCPP and migraine. Headache 1992;32:242-4
20. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989;25:569-75
21. Murphy DL, Lesch KP, Aulakh CS, Pigott TA. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1991;43:527-52
22. Pettibone DJ, Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 1984; 33:1531-5
23. Fuller RW, Snoddy HD, Mason NR, Owen JE. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 1981;20:155-62
24. 3H)-SHT from human perfused platelets. Br J Clin Pharmacol 1993;35:473-8
25. Del Bene E, Anselmi B, Del Bianco PL, Fanciullacci M, Galli P, Salmon S, Sicuteri F. Fenfluramine headache: a biochemical and monoamine receptorial human study. In: Sicuteri F, editor. Headache: New vistas. Florence: Biomedical Press, 1977:101-9
26. Poggioni M, Bonazzi A, Del Bene E, Sicuteri F. Focus on latent nociceptive dysfunction in humans. In: Sicuteri F, Terenius L, Vecchiet L, Maggi CA, editors. Advances in pain research and therapy New York: Raven Press, 1992;20:269-80
27. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993;53:447-63
28. Myers JE, Mieczkowski T, Perel J, Abbondanza D, Cooper TB, Mann JJ. Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders. Biol Psychiatry 1994;35:112-20
29. Goodwin GM, Murray CL, Bancroft J. Oral d-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in man. J Affective Dis 1994;30:117-22
30. Garattini S, Mennini T, Bendotti C, Invernizzi R, Samamin R. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite 1986;7 Suppl:15-38
31. Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 1988;30:715-21
32. Sarkissian CF, Wurtman RJ, Morse AN, Gleason R. Effects of fluoxetine or d-fenfluramine on serotonin release from, and levels in, rat frontal cortex. Brain Res 1990;529:294-301
33. 3H)serotonin. Naunyn Schmiedebergs Arch Pharmacol 1992;345:1-6
34. Mennini T, Bizzi A, Caccia S, Codegoni A, Fracasso C, Frittoli E, et al. Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 1991;343:483-90
35. Bonanno G, Fassio A, Severi A, Ruelle A, Raiteri M. Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism. J Neurochem 1994;63:1163-6
36. Zaczek R, Battaglia G, Culp S, Appel NM, Contrera JF, De Souza EB. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data. J Pharmacol Exp Ther 1990;253:104-12
37. McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J, Ricaurte G. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 1994;269:792-8
38. Celada P, Martin F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994;55:1237-43
39. Caccia S, Ballabio M, Guiso G, Rocchetti M, Garattini S. Species differences in the kinetics and metabolism of fenfluramine isomers. Arch Int Pharmacodyn 1982;258:15-28
40. Gibson EL, Kennedy AJ, Curzon G. d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5HT receptors. Eur J Pharmacol 1993;242:83-90
41. Peatfield RC, Fozard JR, Clifford Rose F. Drug treatment of migraine. In: Clifford Rose F, editor. Handbook of clinical neurology. Amsterdam: Elsevier, 1986;4:173-216
42. Orholm M, le Fèvre Honoré P, Zeeberg I. Prophylactic treatment of migraine with femoxetine - a randomized comparison with placebo. Cephalalgia 1985;5 Suppl 3:516-17
43. Bengtsson B-O, Wiholm B-E, Myrhed M, Walinder J. Adverse experiences during treatment with zimeldine on special licence in Sweden. Int Clin Psychopharmacol 1994;9:55-61
44. Sandrini G, Ruiz L, Patruno G, Bussone G, Verri AP, Nappi G. Antalgic and antidepressant activities of fluoxetine in daily chronic headache. Cephalalgia 1991;11 Suppl 11:280-1
45. Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache 1994;34:20-4
46. Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994;34:44-9
47. Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502
48. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32:101-4
49. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994;34:476-8
50. Saper JR, Silberstein SD, Lake III AE, Winters ME. Fluoxetine and migraine: comparison of double-blind trials. Headache 1995;35:233
51. Markley HG, Gasser PA, Markley ME, Pratt SM. Fluoxetine in prophylaxis of headache: clinical experience. Cephalalgia 1991;11 Suppl 11:164-5
52. Bittman B, Emanuele S. Fluoxetine: side effects and efficacy in a headache population. Headache Q 1992;3:82-5
53. Foster CA, Bafaloukos J. Paroxetine in the treatment of chronic daily headache. Headache 1994;34:587-9
54. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry 1988;153 Suppl 3:77-86
55. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53 Suppl 2:61-6
56. Pande AC, Sayler ME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 1993;8:267-9
57. Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology and therapeutic use in depressive illness. Drugs 1993;46:895-924
58. Wood A. Pharmacotherapy of bulimia nervosa - experience with fluoxetine. Int Clin Psychopharmacol 1993;8:295-9
59. Coquoz D, Porchet HC, Dayer P. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther 1993;54:339-44
60. Borys DJ, Setzer SC, Ling LJ, Reisdorf JJ, Day LC, Krenzelok EP. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992;10:115-20
61. Fuller RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994;55:163-7
62. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992;50:1683-90
63. Fuller RW. Microdialysis studies with 5HT reuptake inhibitors. Trends Pharmacol Sci 1993;14:397
64. Rutter JJ, Auerbach SB. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 1993;265:1319-24
65. 3H)serotonin. Life Sci 1995;56:785-91
66. Artigas F. 5HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993;14:262
67. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 1994;260:251-5
68. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993;16:387-400
69. Caccia S, Fracasse C, Garattini S, Guiso G, Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 1992;31:343-7
70. Caccia S, Anelli M, Codegoni AM, Fracasso C, Garattini S. The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. Br J Pharmacol 1993;110:355-9
71. Trouvin JH, Gardier AM, Chanut E, Pages N, Jacquot C. Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. Life Sci 1993; 52:187-92
72. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5
73. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987;93: 193-200
74. Wong DT, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 1991;5:43-7
75. Ostfeld AM. Migraine headache. Its physiology and biochemistry. JAMA 1960;174:1188-90
76. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10:107-11
77. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967;16:544-52
78. Somerville BW. Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology 1976;26:41-5
79. Panconesi A, Franchi G, Anselmi B, Curradi C. On the mechanisms of sumatriptan side effects. In: Fusco BM, Giacovazzo M, editors. Proc Int Workshop "Unilateral headaches: focus on recent advances". Rome: RS Editore, 1994:111-16
80. Panconesi A. Azione vasocostrittiva del sumatriptan nei vasi periferici dell'uomo. Confinia Cephalalgica 1994;3:5-12
81. 1 receptor agonist, on circulating ACTH and cortisol concentrations in man. Br J Clin Pharmacol 1995;39:389-95
82. Queiroz LP, Weeks RE, Rapoport AM, Sheftell FD. Early and transient side effects of repetitive intravenous dihydroergotamine. Headache 1995;35:294
83. 1C receptor agonists in piglet choroid plexus. Br J Pharmacol 1991;104:45-48
84. 1 receptor subtypes. Headache 1993;33:347-50
85. 1-like receptors by endogenous nitric oxide. Br J Pharmacol 1995;114:969-74
86. 1D subtype. Br J Pharmacol 1992;106:703-9
87. Martin GR, Browning C, Giles H. Further characterization of an atypical 5HT receptor mediating endothelium-dependent vasorelaxation. Br J Pharmacol 1993;110:137P
88. 1c-like receptors. Naunyn Schmiedebergs Arch Pharmacol 1993;347:471-7
89. 2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 1995;114:400-4
90. 1A receptors in nitric oxide-dependent dilatation caused by serotonin in the human forearm vascular bed. J Cardiovasc Pharmacol 1994;24:454-61
91. O'Connor JJ, Kruk ZL. Pharmacological characteristics of 5-hydroxytryptamine autoreceptors in rat brain slices incorporating the dorsal raphe or the suprachiasmatic nucleus. Br J Pharmacol 1992;106:525-32
92. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5HT in the guinea pig. Neuropharmacology 1990;29:511-13
93. Anthony M, Regaglia F, Yang M. The effect of sumatriptan on platelet 5HT in vitro. In: Clifford Rose F, editor. New advances in headache research: 4. London: Smith-Gordon, 1994:179-82
94. Mitsikostas DD, Papadopoulou-Daifotis Z, Sfikakis A, Varonos D. The effect of sumatriptan on brain monoamines in rats. Headache 1996;36:29-31
95. La Porta LD. Recurrent depression after sumatriptan administration for treatment of migraine. J Clin Psychopharmacol 1995;15:81-2
96. Gelenberg AJ. Buspirone: seven-year update. J Clin Psychiatry 1994;55:222-9
97. Pascual J, Berciano J. An open trial of buspirone in migraine prophylaxis. Preliminary report. Clin Neuropharmacol 1991;14:245-50
98. 3 receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology 1994;33:509-13
99. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, et al., and the Ondansetron Study Group. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118:407-13
100. Siderov J, Zalcberg J, Chambers B, Fabinyi G. Migraine following the use of a 5-hydroxytryptamine antagonist. Aust NZ J Med 1993;23:527-8
101. Sicuteri F, Panconesi A, Franchi G, Del Bianco PL, Anselmi B. Impaired 5-hydroxytryptamine tachyphylaxis in migraine. Cephalalgia 1983;3:139-42
102. Maertens de Noordhout A, Wang W, Schoenen J. Clinical neurophysiology and neurotransmitters. Cephalalgia 1995; 15:301-9
103. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 1993;33:173-87
104. 18F-fluorosetoperone. Cephalalgia 1995;15:104-8
105. Glover V, Ahmed F, Hussein N, Jarman J, Adams D, Mackintosh D, Peatfield R. Fenfluramine induced headache: characteristic and biochemistry. Cephalalgia 1996;16:364-5
106. Cowen PJ. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 1993;16 Suppl 3:S6-18
107. Gordon ML, Lipton RB, Brown S-L, van Praag HM. The neuroendocrine challenge paradigm in headache research. Cephalalgia 1995;15:292-6
108. Coccaro EF, Silverman JM, Klar HM, Horvath TB, Siever LJ. Familial correlates of reduced central serotoninergic system function in patients with personality disorders. Arch Gen Psychiatry 1994;51:318-24
109. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-66
110. Caccia S, Conforti I, Duchier J, Garattini S. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days. Eur J Clin Pharmacol 1985;29:221-4
111. McBride PA, Tierney H, DeMeo M, Chen J-S, Mann JJ. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry 1990;27:1143-55
112. Walsh AES, Oldman AD, Franklin M, Fairburn CG, Cowen PJ. Dieting decreases plasma tryptophan and increases the prolactin response to d-fenfluramine in women but not in men. J Affect Dis 1995;33:89-97
113. O'Keane V, O'Hanlon M, Webb M, Dinan T. D-fenfluramine/ prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol 1991;34: 289-92
114. Yatham LN, Barry S, Dinan TG. Serotonin receptors, buspirone, and premenstrual syndrome. Lancet 1989;i:1447-8
115. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotoninergic activity in postmenopausal women. Biol Psychiatry 1995;37:434-41
116. Dhall U, Cowen T, Haven AJ, Burnstock G. Effect of oestrogen and progesterone on noradrenergic nerves and on nerves showing serotonin-like immunoreactivity in the basilar artery of the rabbit. Brain Res 1988;442:335-9
117. Shay J, Futo J, Badrov N, Moss J. Estrogen withdrawal selectively increases serotonin reactivity in rabbit basilar artery. Life Sci 1994;55:1071-81
118. MacGregor EA. "Menstrual" migraine: towards a definition. Cephalalgia 1996;16:11-21
119. Meyler WJ. Side effects of ergotamine. Cephalalgia 1996;16:5-10
120. Panconesi A, Curradi C, Anselmi B, Franchi G. Sex differences in headache sufferers' responsiveness to painful over-distension of the hand-forearm veins. Funct Neurol 1994;9: 133-9
121. Tollefson GD. Anxiety and alcoholism: a serotonin link. Br J Psychiatry 1991;159 Suppl 12:34-9
122. Glover V, Pattichis K, Jarman J, Peatfield R, Sandler M. How does red wine cause migraine? In: Clifford Rose F, editor. New advances in headache research: 3. London: Smith Gordon, 1994:145-50
123. Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. NeuroReport 1993;5:87-9
124. Gemine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 1994;54:115-33
125. Olesen J, Thomsen LL, Lassen LH, Olesen IJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 1995;15:94-100
126. Michalicek J, Gordon V, Lambert G. Reactions of the middle meningeal artery of the cat to neural and humoral stimulation. Cephalalgia 1996;16:27-36
127. Gartside SE, Cowen PJ, Sharp T. Effect of 5-hydoxy-1-tryptophan on the release of 5HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharmacology 1992; 31:9-14
128. Sharp T, Bramwell SR, Grahame-Smith DG. Effect of acute administration of 1-tryptophan on the release of 5HT in rat hippocampus in relation to serotoninergic neuronal activity: an in vivo microdialysis study. Life Sci 1992;50:1215-23
129. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1990;47:411-8
130. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
131. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23
132. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996; 16:323-7
133. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995;15:106-9
134. Leung M, Ong M. Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache 1995;35:488-9
135. Del Bene E, Poggioni M, De Tommasi F. Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 1994;34:536-8
136. Okuyama S, Shimamura H, Hashimoto S, Aihara H. Relation between yawning behavior and central serotonergic neural system in rats. Naunyn Schmiedebergs Arch Pharmacol 1987;335:667-72
137. Mathiau P, Escurat M, Abineau P. Immunohistochemical evidence for the absence of central neuron projection to pial blood vessels and dura mater. Neuroscience 1993; 52:667-76
138. 1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 1989;86:6793-97
139. 2B receptor. Mol Pharmacol 1994;46:227-34
140. Sicuteri F. Quasi-phantom head pain from functional deafferentation. Clin J Pain 1987;3:63-80
141. Wallis DI, Wu J, Wang XC. Is 5-hydroxytryptamine mediating descending inhibition in the neonatal rat spinal cord through different receptor subtypes? Eur J Pharmacol 1993;250:371-7
142. Eide PK, Hole K. The role of 5-hydroxytryptamine (5HT) receptor subtypes and plasticity in the 5HT systems in the regulation of nociceptive sensitivity. Cephalalgia 1993;13:75-85
143. Sanchez A, Niedbala B, Feria M. Modulation of neurophatic pain in rats by intrathecally injected serotonergic agonists. NeuroReport 1995;6:2585-8
144. Kishore-Kumar R, Schafer SC, Lawlor BA, Murphy DL, Max MB. Single doses of serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989;37:223-7
145. O'Connell MT, Portas CM, Sarna GS, Curzon G. Effect of p-chlorophenylalanine on release of 5-hydroxytryptamine from the rat frontal cortex in vivo. Br J Pharmacol 1991;102:831-6
146. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-9
147. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 1995; 66:339-69